Pfizer Blog

Pfizer announces the start of phase 3 clinical trials in adults for its investigational vaccine against Respiratory Syncytial Virus (RSV)

Excerpt Pfizer has initiated RENOIR, a Phase 3 clinical trial of the Respiratory Syncytial Virus (RSV) bivalent prefusion F subunit investigational vaccine candidate in adults ages 60 or older. RSV is a contagious, seasonal illness, and a common and pervasive cause of severe acute respiratory illness in older adults with no vaccine currently available. The […]

Moderna Blog

Moderna Announces Significant Advances Across Industry-Leading mRNA Portfolio at 2021 R&D Day

Excerpt Moderna announces significant advancements to be presented at its annual R&D Day, including a combination booster vaccine for COVID-19 and seasonal flu, a pediatric combination candidate for RSV and hMPV, promising interim Phase 1 data for an RSV vaccine candidate, an infectious disease therapeutic vaccine candidate, and full enrolment for a Phase 2 study […]

Novavax Initiates Phase 1/2 Clinical Trial Combination Vaccine for COVID-19 and Seasonal Influenza

Novavax Initiates Phase 1/2 Clinical Trial Combination Vaccine for COVID-19 and Seasonal Influenza

Excerpt Novavax has enrolled the first participants in a Phase 1/2 clinical trial of a combination vaccine using its seasonal influenza and COVID-19 vaccines, together with its patent saponin-based Matrix-M TM adjuvant. Both vaccines have individually demonstrated strong results. The study will evaluate the immunogenicity and safety of multiple formulations of the combination vaccine administered […]

GSK announces FDA approval for Nucala (mepolizumab) for use in adults with chronic rhinosinusitis with nasal polyps

by Kashmiira Nayar

Excerpt The FDA has approved GSK’s Nucala (mepolizumab) as an add-on treatment in the US for adults with chronic rhinosinusitis with nasal polyps (CRSwNP). Mepolizumab is the first anti- interleukin-5 therapy to be approved for CRSwNP, which affects over 5 million in the US, caused by raised eosinophil levels resulting in the formation of nasal […]

IVI News Image

IVI Partners with SK Bioscience to Conduct Late Stage Global Clinical Trials of SK Bioscience’s Recombinant Protein Vaccine Candidate (GBP510)

Excerpt The International Vaccine Institute (IVI) will be conducting Phase 3 clinical trials of SK bioscience’s recombinant protein vaccine candidate (GBP510) in Europe and Southeast Asia, with the aim of bringing it to market in 2022. Additionally, IVI has formed a partnership with SK and the Korean National Institute of Health (KNIH) to jointly conduct […]


SINOVAC Announces Positive Data on Booster Dose of CoronaVac ®

by Kashmiira Nayar

Excerpt Results from an ongoing phase 2 clinical trial studying immunogenicity, safety, and immune persistence of CoronaVac ® show that while good immune memory is generated after the second dose, a third dose induces a stronger immune response, with an even lower adverse reaction rate after the third dose as compared to the second. A […]

Vigil Neuroscience Completes $90 million Series B Financing to Advance a Pipeline of Microglia-targeted Medicines to Treat Rare and Common Neurodegenerative Diseases

by Kashmiira Nayar

Excerpt Vigil Neuroscience has secured $90 million in its Series B financing led by Vida Ventures with participation from new as well as existing investors. This will propel the advancement of Vigil’s proprietary microglia-focused medicine line-up for the treatment of neurodegenerative diseases. Development of the antibody, VGL101, and triggering receptor on myeloid cells 2 (TREM2) […]

Lonza to Introduce Drug Product Manufacturing Services in Guangzhou, China

by Kashmiira Nayar

Lonza announced its plans to invest in establishing drug product manufacturing capabilities at its site in Guangzhou, China. The new investment will fund the installation of an aseptic drug product fill and finish production line at the 17,000 m2 state-of-the-art cGMP mammalian facility. This will significantly expand the site’s capabilities, supporting global and domestic customers […]

Pfizer Blog

Pfizer Announces Positive Top-line Results from Phase 2B/3 of Ritlecitinib in Alopecia Areata

by Kashmiira Nayar

Excerpt Pfizer announces positive top-line results from the Phase 2b/3 ALLEGRO trial of once-daily ritlecitinib for the treatment of alopecia areata. Ritlecitinib 50 mg and 30 mg showed significantly a greater proportion of patients with 20 percent or less scalp hair loss after 24 weeks of treatment versus placebo, achieving the primary efficacy endpoint of […]

Moderna Announces First Participant Dosed in Pase 1/2 Study of Its Quadrivalent Seasonal Flu mRNA Vaccine

Moderna Announces First Participant Dosed in Phase 1/2 Study of Its Quadrivalent Seasonal Flu mRNA Vaccine

by Kashmiira Nayar

Excerpt Moderna has dosed the first participants in its Phase 1/2 study of mRNA-1010, the company’s first quadrivalent seasonal influenza mRNA vaccine candidate to enter the clinic. The study will enroll 180 adult participants in the U.S. and targets WHO recommendations for the prevention of influenza, which causes respiratory illnesses and significant economic burdens on […]